Does bortezomib influence pre-transplant desensitization therapy or benefit post-heart transplant outcomes for highly sensitized patients?

Manvir DhillonJon A KobashigawaMichelle M KittlesonRashmi JainNikhil J PatelTahli Singer-EnglarXiaohai ZhangMatthew HakimiTamar AintablianRobert VescioDeanna DiliberoEvan P KransdorfLawrence CzerAndriana P NikolovaJignesh K Patel

Published in: Clinical transplantation (2023)

The use of bortezomib in highly sensitized patients does not significantly lower circulating antibodies prior to heart transplantation. However, its use may improve the chances of obtaining an immuno-compatible donor heart and contribute to acceptable post-transplant outcomes.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
heart failure
peritoneal dialysis
prognostic factors
stem cells
multiple myeloma
type diabetes
atrial fibrillation
patient reported outcomes
mesenchymal stem cells
patient reported
bone marrow
weight loss